A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients 'CapTere'.
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Capecitabine (Primary) ; Docetaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CapTere
- 31 Aug 2018 Biomarkers information updated
- 21 Sep 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 21 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.